Diagnosis and therapy of osteoporosis. Strategy for effective treatment after fragility fractures;Diagnostik und therapie der osteoporose. Strategie für eine effiziente prävention von folgefrakturen

Unfallchirurg

Volumn 106, Issue 7, 2003, Pages 526-541

  Bartl, Reiner ^a   Bartl, C ^b   Mutschler, W ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Diagnosis; Drugs; Fractures; Osteoporosis; Secondary prevention; Strategy for effective treatment

Indexed keywords

AGENTS AFFECTING METABOLISM; ALENDRONIC ACID; ANTIRESORPTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CALCITONIN; CALCIUM; CELECOXIB; CODEINE; DICLOFENAC; DIHYDROCODEINE; DIPYRONE; FENTANYL; GESTAGEN; HYDROMORPHONE; IBANDRONIC ACID; IBUPROFEN; LEVOMETHADONE; MORPHINE; NALOXONE; NAPROXEN; OPIATE; OSTEOANABOLIC AGENT; OXYCODONE; PAMIDRONIC ACID; PARACETAMOL; RALOXIFENE; RISEDRONIC ACID; ROFECOXIB; TILIDINE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

AGING; ARTICLE; BONE DENSITY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; FEMALE; FRAGILITY FRACTURE; GENERAL PRACTITIONER; GERMANY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MONITORING; OSTEOLYSIS; OSTEOPOROSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SECONDARY PREVENTION; TREATMENT INDICATION; TREATMENT OUTCOME;

CALCIUM; DENSITOMETRY, X-RAY; DIPHOSPHONATES; EARLY DIAGNOSIS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; VITAMIN D;

EID: 0042567227     PISSN: 01775537     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00113-003-0642-5     Document Type: Article

References (74)

1. Banse X (2002) When density fails to predict bone strength. Acta Orthop Scand 73, Suppl 303:S2-S53
2. Barlow D, Francis R, Miles A (2001) The Effective Management of Osteoporosis. Aesculapius Medical Press, London San Francisco Sydney
3. Bartl R (2001) Osteoporose - Prävention, Diagnostik, Therapie. Thieme, Stuttgart New York
4. Bartl R (2002) Osteoporose: Was ist gesichert in der Therapie? Internist 43:1529-1543
5. Bartl R, Frisch B (1993) Biopsy of Bone in Internal Medicine - An Atlas and Sourcebook. Kluwer Academic Publishers, Dordrecht Boston London
6. Bartl R, Frisch B (2001) Das Bisphophonat-Manual - Wirkungen, Indikationen, Strategien, Trends. Blackwell, Berlin
7. Bestehorn K, Raspe H, Götte S et al. (2002) Berücksichtigung der Osteoporose bei der Therapie nichtvertebraler Frakturen - Pilotstudie zum FX-Register. (2002) Zeitschr Rheumatol 61, Suppl. 1:80
8. Bestehorn K, Zink A, Dreher R et al. (2002) Pharmakotherapie bei postmenopausaler Osteoporose. Analyse der Versorgungssituation. Zärztl Fortbild Qualsich 96:699-704
9. Bischoff H, Stähelin H, Dick W et al. (2003) Effects of vitamin D and calcium supplementation on falls: a randomized controlled study. J Bone Miner Res 18:343-351
10. Black D, Cummings S, Karpf D et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
11. Black D, Thompson D, Bauer D et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118-4124
12. Bone H, Adami S, Rizzoli R et al. (2000) Weekly administration of alendronate: rationale and plan for clinical assessment. Clinical Therapeutics 22:15-28
13. Chapuy M, Arlot M, Duboeuf F et al. (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637-1642
14. Chavassieux P, Arlot M, Reda C, Wei L, Yates A, Meunier P (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1000:1475-1480
15. Chesnut C, McClung M, Ensrud K et al. (1995) Alendronate treatment of the postmenopausal osteoporotic women: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152
16. Chesnut C, Silverman S, Andriano K et al. (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267-276
17. Chevally T, Hoffmeyer P, Bonjour J-P et al. (2002) An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int 13:450-455
18. Cranney A, Guyatt G, Griffith L et al. (2002) IX summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 23:570-578
19. Cummings S, Black D Thompson D et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082
20. Dawson-Hughes B, Harris S, Krall E, Dallal G (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:1437-1443
21. Dempster D (2002) The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int 13:349-352
22. Dempster D, Cosman F, Kurland E et al. (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846-1853
23. Ettinger B, Black D, Mitlak B et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomised clinical trial. JAMA 282:637-645
24. Fleisch H (2001) Can bisphosphonates be given to patients with fractures? J Bone Miner Res 16:437-440
25. Follin S, Black J, McDermott M (2003) Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 23:190-198
26. Freedman K, Kaplan F, Bilker w et al. (2000) Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surgery 82:1063-1070
27. Gardner M, Flik K, Mooar P et al. (2002) Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surgery 84:1342-1348
28. Gerdhem P, Obrant K (2002) Effects of cigarette-smoking on bone mass as assessed by dual-energy X-ray absorptiometry and ultrasound. Osteoporos Int 13:933-936
29. Götte S, Dittmar K (2001) Epidemiologie und Kosten der Osteoporose. Orthopäde 30:402-404
30. Hadji P, Rabe T, Ortmann O et al. (2002) Möglichkeiten und Grenzen der Osteoporoseprävention durch Östrogene und Gestagene. Geburtsh Frauenheilk 62:436-445
31. Häuselmann H, Rizzoli R (2003) A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 14:2-12
32. Haguenauer D, Welch V, Shea B et al. (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727-738
33. Harris S, Watts N, Genant G et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344-1352
34. Heinemann D (2000) Osteoporosis. An overview of the National Osteoporosis Foundation cinical practice guide. Geriatrics 5S:31-36
35. Hochberg M, Greenspan S, Wasnich R et al. (2002) Changes in bone density and turnover explain the reduction in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1S86-1S92
36. Hosking D, Ringe J (2000) Treatment of Metabolic Bone Disease - Management Strategy and Drug Therapy. Martin Dunitz, London
37. Hosking D, Chilvers C, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485-492
38. Johnell O, Kannus P, Obrant K et al. (2001) Management of the patient after an osteoporotic fracture: guidelines for orthopedic surgeons. Acta Orthop Scand 72:325-330
39. Johnell O, Oden A, De Laet C et al. (2002) Biochemical markers and the assessment of fracture probability. Osteoporos Int 13:523-526
40. Juby A, De Geus-Wenceslau C (2002) Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 13:205-210
41. Kamel H, Hussain M, Tariq S et al. (2000) Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture. Amer J Med 109:326-328
42. Kanis J, Johnell O, Oden A et al. (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. 12:989-995
43. Liberman U, Weiss S, Bröll J et al. for the Alendronate Phase III Osteoporois Treatment Study Group (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
44. Lips P, Graafmans W, Ooms M, et al. (1996) Vitamin D supplementation and fracture incidence in elderly persons. A randomized placebo-controlled trial. Ann Intern Med 124:400-406
45. Marcus R, Wong M, Heath H et al. (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Reviews 23:16-37
46. Maricic M, Aachi J, Meunier P et al. (2000) Raloxifen 60mg/day has effects within 12 months in postmenopausal osteoporosis treatment and prevention studies. Arthritis Rheum 43(9Suppl):197-201
47. Marshall D, Johnell O, Wedel H et al. (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312:1254-1259
48. Matziolis G, Rau H, Klever et al. (2002) Beeinflussung humaner Osteoblasten durch verschiedene Analgetika. Unfallchirurg 105:527-531
49. McClung M, Eastell R, Benhamouu L et al. (2001) Risedronate reduces hip fractures in elderly postmenopausal women. N Engl J Med 344:333-340
50. Melton L, Heaney R (2003) Too much medicine? Or too little? Bone 32:327-331
51. Minne H, Pfeifer M (2003) Evidenzbasierte Therapie der Osteoporose. Dtsch Med Wochenschr 128:931-934
52. Neer R, Arnaud C, Zanchetta J et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
53. O'Gradaigh D, Debiram I, Love S et al. (2003) A prospective study of discordance in diagnosis of osteoporosis using spine and proximal femur bone densitometry. Osteoporos Int 14:13-18
54. Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
55. Pal B (1999) Questionnaire survey of advice given to patients with fractures. BMJ 318:S00-S01
56. Pols H, Felsenberg D, Hanley D, et al. (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 9:461-468
57. Ravn P, Neugebauer G, Christiansen C (2002) Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 30:320-324
58. Reginster J, Minne H, Sorensen O et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
59. Recker R, Hinders S, Davies K et al. (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11:1961-1966
60. Reid I, Ames R, Evans M, Gamble G, Sharpe S (1995) Long-term effect of calcium supplementation on bone loss and fracture in postmenopausal women: a randomized controlled trial. Am J Med 98:331-335
61. Reid I, Brown J, Burckhardt P et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
62. Roschger P, Rinnerthaler S, Yates J et al. (2001) Alendronate increases degree and uniformity of mineralisation in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191
63. Rubin M., Cosman F, Lindsay R, Bilezikian J (2002) The anabolic effect of parathyroid hormone. Osteoporos Int 13:267-277
64. Saag K, Emkey R, Schnitzer T et al. (1998) Alendronate for the treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299
65. Sorensen O, Crawford G, Mulder H et al. (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32:120-126
66. Thiébaud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307
67. Tonino R, Meunier P, Emkey R et al. (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85:3109-3115
68. Torgenson D, Bell-Seyer S (2001) Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285:2891-2897
69. Torgerson D, Dolan P (1998) Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 57:378-379
70. Turner C (2002) Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 13:97-104
71. Van Staa T, Leufkens H, Cooper C (2002) Does a fracture at one site predict later fractures at other sites? A british cohort study. Osteoporos Int 13:624-629
72. Wallach S, Cohen S, Reid D et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285
73. Watts N, Harris S, Genant H et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
74. Women's Health Initiative Group (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333